Israel is negotiating for the rights to purchase a coronavirus vaccine being developed by Oxford University and AstraZeneca.

The ChAdOx1 nCoV-19 coronavirus vaccine is safe and produced an immune response in early-stage clinical trials, according to the results of the vaccine’s Phase I/II trial, which were were published in The Lancet medical journal on Monday.

Although the British company’s policy is to sell the vaccine to international organizations to avoid favoring one country over another, Israel has contacted the company directly, and according to Israeli Health Ministry officials is working through multiple channels to secure as large a supply of vaccines as possible, as quickly as possible.

Thus far, Israel has only signed a deal to purchase vaccines with the firm Moderna. But given that it is unclear which vaccine will be finished and approved first, Israel expects to sign more deals with other firms.

AstraZeneca Israel said in response to the reports that “as part of efforts to make the vaccine accessible, a decision has been made that international groups and organizations will handle any future distribution of the vaccine between the countries of the world.”

It continued: “The pharmaceutical company is working day and night to supply a vaccine for COVID-19, if one is found to be safe and effective in the final stage of clinical trials. AstraZeneca is working constantly with the Health Ministry to make vaccines available to the people of Israel.”

This article first appeared in Israel Hayom.

Support Jewish Journalism
with 2020 Vision

One of the most intriguing stories of the sudden Coronavirus crisis is the role of the internet. With individuals forced into home quarantine, most are turning further online for information, education and social interaction.

JNS's influence and readership are growing exponentially, and our positioning sets us apart. Most Jewish media are advocating increasingly biased progressive political and social agendas. JNS is providing more and more readers with a welcome alternative and an ideological home.

During this crisis, JNS continues working overtime. We are being relied upon to tell the story of this crisis as it affects Israel and the global Jewish community, and explain the extraordinary political developments taking place in parallel.

Our ability to thrive in 2020 and beyond depends on the generosity of committed readers and supporters. Monthly donations in particular go a long way in helping us sustain our operations. We greatly appreciate any contributions you can make during these challenging times. We thank you for your ongoing support and wish you blessings for good health and peace of mind.